Meta-analysis · people
Cerebrolysin: small cognitive gain in vascular dementia, weak evidence
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
For vascular dementia, Cerebrolysin's support comes from a small set of biased trials showing modest gains, so its real-world value is still unproven.
- Kind
- Meta-analysis
- Studied in
- People
- Number studied
- 597
- Published
- 2019
- Journal
- Cochrane Database Syst Rev
What they tested
The team asked whether Cerebrolysin improves thinking, overall function and survival in people with vascular dementia, and whether it causes side effects.
How the study was done
A Cochrane systematic review and meta-analysis, which pools results from many studies, of randomized controlled trials with 597 people, mostly with mild to moderate vascular dementia. The trials used different doses and treatment lengths and followed people for 15 days to 3 years.

What they found
In pooled data from 420 people, Cerebrolysin improved scores on thinking tests (MMSE or ADAS-cog+) with a standardized mean difference of 0.36 (95% CI 0.13 to 0.58). A standardized mean difference is a way to combine results from different test scales. In pooled data from 379 people, those on Cerebrolysin were more likely to respond on overall function ratings (risk ratio 2.69, 95% CI 1.82 to 3.98), and side effect rates did not differ (risk ratio 0.91, 95% CI 0.29 to 2.85). The one trial that tracked deaths had none, and all of this evidence was rated very low quality.
What it doesn’t show
The trials were few, had a high risk of bias, and differed a lot from each other, and every trial that named a funder was paid for by the drug industry. No trial measured quality of life or caregiver burden, and the authors noted any benefit might be too small to matter in daily care.
The paper
Cui et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019.
The compound
More studies on Cerebrolysin
- Cerebrolysin: better NIHSS scores after stroke across nine trialsMeta-analysis · people · 2018
- Cerebrolysin beat placebo on global change in Alzheimer's at 6 monthsMeta-analysis · people · 2015
- Cerebrolysin: better arm function at day 90 after stroke in CARSRandomized trial · people · 2016
- Cerebrolysin: no overall benefit in acute ischemic stroke at 90 daysRandomized trial · people · 2012
- Cerebrolysin after thrombectomy: 68% vs 44% independent at 90 daysClinical trial · people · 2025
- Every study on Cerebrolysin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.